Clinical Data AAIC 2026: Lilly keeps door open for maintenance Kisunla after amyloid clearance BioSpaceEli Lilly's anti-amyloid Alzheimer's drug is designed to be stopped after patients drop below a certain amyloid level in the brain.NeuroscienceRead full story pharminent July 15, 2026 (Last updated: July 17, 2026) BioSpace Eli Lilly’s anti-amyloid Alzheimer’s drug is designed to be stopped after patients drop below a certain amyloid level in the brain. Neuroscience Read full story Post navigation Previous: Celcuity gets FDA nod for first-in-class breast cancer drugNext: AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug Related Stories Clinical Data Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts pharminent September 2, 2026 Clinical Data Novartis says MS pill succeeds in two large studies pharminent September 1, 2026 Clinical Data ESC 2026: Evolocumab explores new frontiers in CV disease prevention pharminent August 31, 2026